BioMarin Licenses UCSF Technology To Address Cause of Cystic Fibrosis
This article was originally published in The Pink Sheet Daily
Executive Summary
UCSF researcher Alan Verkman will have an ongoing role in lead optimization and development, BioMarin’s CEO tells “The Pink Sheet” DAILY.
You may also be interested in...
Vertex Advance In Cystic Fibrosis May Treat The Underlying Disease
10 percent increase in lung function seen in Phase IIa could mean five to 10 years for some CF patients if outcome is sustained in further trials.
Vertex Advance In Cystic Fibrosis May Treat The Underlying Disease
10 percent increase in lung function seen in Phase IIa could mean five to 10 years for some CF patients if outcome is sustained in further trials.
BioMarin Submits Kuvan For Phenylketonuria
Firm is asking FDA for a priority review, which would potentially allow for a late 2007 launch of the orphan drug.